FXN and Friedreich ataxia: A pilot open label, 8 weeks study in 10 FRDA patients, reported increased frataxin levels, reduced expression of oxidative stress markers and improvement in neurological performances, as measured by the Scale for the Assessment and Rating of Ataxia (SARA) score (Boesch et al., 2007).